Abstract: Disclosed herein are novel formulations containing relacorilant ((R)-(1-(4-fluorophenyl)-6-(1-methyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-hexahydro-1H-pyrazolo[3,4-g]isoquinolin-4a-yl)(4-(trifluoromethyl)pyridin-2-yl)methanone) that are suitable for administration, including oral administration, to patients suffering from disorders amenable to treatment by glucocorticoid receptor modulators (GRMs). Single unit dosage forms comprise softgel capsules containing these formulations. Such softgel capsules may contain, e.g., relacorilant formulations containing 25 milligrams (mg), 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, or other amounts of relacorilant. These novel formulations and single unit dosage forms may be used to treat diseases and disorders including Cushing's syndrome, Cushing's Disease, and other disorders.
Type:
Grant
Filed:
September 22, 2022
Date of Patent:
March 12, 2024
Assignee:
Corcept Therapeutics Incorporated
Inventors:
Ian Scott, Travis Lemons, Yip-Fong Chia
Abstract: A composition of at least one cannabinoid in a specific amount, and at least one primary terpene in a specific amount, where a total terpenes to total cannabinoids weight/weight ratio in the composition is from about 0.05 to about 1.0.
Type:
Grant
Filed:
February 28, 2023
Date of Patent:
March 12, 2024
Assignee:
BUZZELET DEVELOPMENT AND TECHNOLOGIES LTD
Abstract: The invention relates to polymorphous crystal modifications of a DPP-IV inhibitor, the preparation thereof and the use thereof for preparing a medicament.
Type:
Grant
Filed:
June 30, 2021
Date of Patent:
March 5, 2024
Assignee:
Boehringer Ingelheim International GmbH
Inventors:
Peter Sieger, Dirk Kemmer, Peter Kohlbauer, Thomas Nicola, Martin Renz
Abstract: An organic compound is represented by general formula [1-1]. In general formula [1-1], X is an oxygen atom, a sulfur atom, a selenium atom, or a tellurium atom, and R1 to R18 are each independently selected from the group consisting of a hydrogen atom, a halogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkoxy group, a substituted or unsubstituted amino group, a substituted or unsubstituted aromatic hydrocarbon group, a substituted or unsubstituted heterocyclic group, a substituted or unsubstituted aryloxy group, a substituted or unsubstituted silyl group, and a cyano group.
Abstract: N?-(2-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-ylthio)acetoxy)-2-naphthimidamide compound, its synthesis, and its use as an antimicrobial agent.
Type:
Grant
Filed:
October 11, 2023
Date of Patent:
February 20, 2024
Assignee:
KING FAISAL UNIVERSITY
Inventors:
Hany Mohamed Abd El-Lateef Ahmed, Mai Mostafa Khalaf Ali, Antar Ahmed Abdelhamid Ahmed, Amer A. Amer
Abstract: Acyclic CB[n]-type compounds, methods of making such compounds, and uses of the compounds. For example, these compounds can be used as nanocontainers to solubilize pharmaceutical agents. Also provided are compositions and methods of using them for therapy or prophylaxis of a wide variety of conditions for which therapy or prophylaxis is desirable.
Type:
Grant
Filed:
December 14, 2020
Date of Patent:
February 13, 2024
Assignee:
University of Maryland, College Park
Inventors:
Lyle David Isaacs, Volker Briken, Gaya Hettiarachchi, Da Ma, Duc M. Nguyen
Abstract: A method for direct synthesis of cyclic carbonates is achieved by reacting at least one epoxide with carbon dioxide in the presence of a choline catalyst, such as choline chloride, under mild conditions such as a temperature between about 25° C. to 150° C. and a pressure of from about atmospheric to 75 psi (0.52 MPa), in a cyclic carbonate solvent. The choline catalyst may be the only catalyst used, and a co-catalyst or hydrogen bond donor is not necessary. The concentration of choline catalyst in the solvent ranges from about 0.5 mol % to about 10 mol %, based on the epoxide.
Type:
Grant
Filed:
March 14, 2022
Date of Patent:
February 13, 2024
Assignee:
Baker Hughes Oilfield Operations LLC
Inventors:
Analette Carrasco, Jerry J. Weers, Catherine C Blackwell, Sankaran Murugesan, Xiaofeng Wang, Douglas Nugent, Corby A. Roberts
Abstract: K-Ras is the most frequently mutated oncogene in human cancer. Disclosed herein are compositions and methods for modulating K-Ras and treating cancer.
Type:
Grant
Filed:
November 23, 2022
Date of Patent:
February 6, 2024
Assignee:
The Regents of the University of California
Inventors:
Jonathan Ostrem, Ulf Peters, Kevan M. Shokat
Abstract: A composition and method for treatment of brittle, broken, cracked or otherwise damaged nail and hoof plates. The composition is an aqueous-organic medium containing a non-covalent complex of a diamine and an organic acid or an aqueous-organic medium with a diamine alone.
Abstract: The invention relates to processes for preparing carbaprostacyclin analogues and intermediates prepared from the processes. The invention also relates to cyclopentenone intermediates in racemic or optically active form.
Abstract: Disclosed herein is a powder for oral suspension and a reconstituted product thereof comprising highly pure hydrochlorothiazide, which is useful for treating hypertension and edema.
Abstract: Disclosed is a method for preventing or treating atopic dermatitis using TRPV1 receptor antagonist. More specifically, it may be possible to prevent and/or treat the atopic dermatitis without any side effects such as an increase in body temperature, epidermal atrophy, and the like by percutaneously administrating a composition for external use on the skin containing the TRPV1 receptor antagonist.
Type:
Grant
Filed:
February 28, 2020
Date of Patent:
January 23, 2024
Assignee:
AMOREPACIFIC CORPORATION
Inventors:
Gyeyoung Choi, Hyunjin Nam, Miyoung Park, Kyoungmi Jung, Jihae Lee, Chang Soon Choi, Youngho Park, Jong Hwa Roh, Eunsil Park, Jaehong Park, Kwanghyun Shin, Byoung Young Woo, Kiwha Lee, Wonkyung Cho, Joonho Choi
Abstract: The present invention generally relates to sensitizer compounds and their use in combination with Tyrosine Kinase Inhibitors (TKIs) for sensitizing tumor, cancer or pre-cancerous cells to TKI treatment. In particular, the present invention relates to administration regimes that combine TKIs such as Gefitinib or Icotinib with TKI-sensitizing DZ1 esters and amides conjugated to statin or platin-based drugs, or to Artemisinin, including, without limitation: DZ1-Simvastatin amide, DZ1-Simvastatin ester, DZ1-Cisplatin ester, and DZ1-Cisplatin amide, DZ1-Artemisinin ester, and DZ1-Artemisinin amide. Furthermore, the present invention relates to improved TKI treatment of cancers by sensitizing tumor, cancer or pre-cancerous cells, in particular cancers that develop TKI resistance, including e.g. lung cancer and pancreatic cancer.
Type:
Grant
Filed:
October 21, 2017
Date of Patent:
January 23, 2024
Assignees:
Da Zen Theranostics, Inc., Cedars-Sinai Medical Center
Inventors:
Liyuan Yin, Yi Zhang, Stefan Mrdenovic, Gina Chia Yi Chu, Ruoxiang Wang, Qinghua Zhou, Jian Zhang, Leland W. K. Chung
Abstract: The present disclosure provides an amorphous solid dispersion containing a Cap-dependent endonuclease inhibitor or a pharmaceutically acceptable salt thereof for oral administration, wherein the Cap-dependent endonuclease inhibitor or a pharmaceutically acceptable salt thereof is dispersed in a matrix formed from the pharmaceutically acceptable polymer. Further disclosed are methods for preparing a above amorphous solid dispersion and a use thereof for treating virus infection and a pharmaceutical composition containing same.
Abstract: Luminescent materials that include a luminescent phosphor compound, articles including a security feature, and methods for producing the luminescent phosphor compounds are provided herein. In an embodiment, a luminescent material includes a medium and luminescent particles. The luminescent particles include a luminescent benzothiazole having a ureido linkage. The luminescent benzothiazole has a peak intensity within a wavelength of from about 555 to about 630 nm in response to excitation with electromagnetic radiation at a wavelength of about 366 nm.
Abstract: Disclosed in certain embodiments is a pharmaceutical formulation (e.g., parenteral formulation) comprising a therapeutically effective amount of nalmefene or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable adjuvant (e.g., parenterally acceptable adjuvant) that promotes the rate at which the nalmefene or salt thereof is more rapidly absorbed into the systemic circulation of a subject identified as in need thereof.
Abstract: The present invention is directed to, in part, fused heteroaryl compounds and compositions useful for preventing and/or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, abnormal late/persistent sodium current. Methods of treating a disease or condition relating to aberrant function of a sodium ion channel including neurological disorders (e.g., Dravet syndrome, epilepsy), pain, and neuromuscular disorders are also provided herein.
Type:
Grant
Filed:
May 30, 2019
Date of Patent:
January 9, 2024
Assignee:
PRAXIS PRECISION MEDICINES, INC.
Inventors:
Andrew Mark Griffin, Brian Edward Marron, Gabriel Martinez Botella, Kiran Reddy, Marion Wittmann
Abstract: The present disclosure provides methods and formulations for reducing ammonia and carbon dioxide emissions from a bovine using lubabegron, or a physiologically acceptable salt thereof. The present disclosure also provides bovine feed additives and bovine feed compositions.
Type:
Grant
Filed:
April 20, 2022
Date of Patent:
January 9, 2024
Assignee:
ELANCO US INC.
Inventors:
Cory T. Herr, John Charles Kube, Jerold Scott Teeter